Frequency of BRAF V600E immunoexpression in ameloblastomas: a multi-institutional analysis of 86 cases in Latin America and comprehensive review of the literature.

Autor: Silveira FM; Department of Diagnostics in Pathology and Oral Medicine Universidad de la República, Montevideo, 16400, Uruguay ronellbologna@odon.edu.uy., Schuch LF, Pereira-Prado V, Sicco E, Almeda-Ojeda O, Molina-Frechero N, Paparella ML, Villarroel-Dorrego M, Hernadez M, Bologna-Molina R

Publikováno v: Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2024 Jul 01; Vol. 29 (4), pp. e509-e516. Date of Electronic Publication: 2024 Jul 01.

Jairo Ojeda o la poética hecha canción. (Spanish)

Autor: Sossa Santos, Jorge Enrique

Publikováno v: Pensamiento, Palabra y Obra; jul-dic2017, Issue 18, p112-117, 6p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Update of the Global Heat Flow Database led by International Heat Flow Commission

Autor: Tanaka, A., Fuchs, S., Beardsmore, G., Chiozzi, P., Espinoza-Ojeda, O., Gola, G., Gosnold, W., Harris, R., Jennings, S., Liu, S., Negrete-Aranda, R., Neumann, F., Norden, B., Poort, J., Rajver, D., Ray, L., Richards, M., Smith, J., Verdoya , M.

Publikováno v: Abstracts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______156::2455f1a05f97bdf42dea89d2ffcb4b3f
https://gfzpublic.gfz-potsdam.de/pubman/item/item_5013518

Depletion of high-content CD14 ⁺ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.

Autor: Wang X; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Borquez-Ojeda O; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stefanski J; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Du F; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Qu J; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chaudhari J; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Thummar K; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhu M; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shen LB; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hall M; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gautam P; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wang Y; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sénéchal B; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sikder D; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Adusumilli PS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Brentjens RJ; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Curran K; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Geyer MB; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mailankhody S; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Cearbhaill R; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Park JH; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sauter C; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Slovin S; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Smith EL; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rivière I; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2021 Jul 16; Vol. 22, pp. 377-387. Date of Electronic Publication: 2021 Jul 16 (Print Publication: 2021).